JANEY PHIPPS: Open Payments
NPI 1245328319 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$795 in 52 payments from 15 companies in 2025. Trend: 2023 $1,684 · 2024 $1,183 · 2025 $795
Food & beverage: $795
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $166 |
| ABBVIE INC. | 13 | $158 |
| Phathom Pharmaceuticals, Inc. | 6 | $106 |
| Novartis Pharmaceuticals Corporation | 4 | $67 |
| Abbott Laboratories | 3 | $63 |
| Ardelyx, Inc. | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Madrigal Pharmaceuticals | 1 | $33 |
| SANOFI-AVENTIS U.S. LLC | 1 | $21 |
| Gilead Sciences, Inc. | 1 | $20 |
Products named: VOQUEZNA, Rybelsus, VRAYLAR, Ozempic, LEQVIO, FREESTYLE LIBRE 3, IBSRELA, XIFAXAN.
Industry payments across KY — which companies pay providers there.
